Redesign Science, a New York-based computational drug discovery, raised $15M in Seed-2 and Seed-3 funding.
The round was led by Collaborative Fund and 5Y Capital, Notation Capital, Third Kind Venture Capital, Preface Ventures, Refactor Capital, Acequia Capital, and Hawktail.
The company intends to use the funds to expand its cloud computing infrastructure and advance several core screening algorithms to scale across a diverse range of biological target classes.
Led by David Rooklin, CEO, and Haotian Li, cofounder and CTO, Redesign Science is a biotech company combining physics, computer science and biotechnology to advance new small molecule therapeutics, ranging from precision cancer therapeutics to first-in-class small molecules for inflammatory bowel disease. It uses computational approaches to understand protein dynamics for precision structure-based drug discovery and to expand the druggable proteome.
FinSMEs
08/12/2021